Phentolamine Mesylate: An Antidote for Local Anesthesia; A Boon in Dentistry

Authors

  • Sumana Devadiga Department of Oral and Maxillofacial Surgery, KVG Dental College, Sullia, India
  • Deepthi Shetty Department of Oral and Maxillofacial surgery, AB Shetty Memorial Dental College and Hospital, Derlakatte, India
  • Shrinivas Hittalmani City Central Hospital, Davangere, India

DOI:

https://doi.org/10.37591/rrjod.v5i1.1027

Abstract

The most frequently administered drugs in dentistry are local anesthetics. Local anesthetics also represent the safest and the most effective drugs available in medicine for both the control and prevention of pain occurring during and following invasive procedures. These not only provide relief from pain during procedures but also leave an inconvenient residual numbness that takes some time to wear off following completion of dental procedures. OraVerse, an injectable formulation of phentolamine mesylate (PM), was recently approved by the U.S. Food and Drug Administration (FDA) for reversal of anesthesia of the lip and tongue and associated functional deficits resulting from an intraoral sub-mucosal injection of a local anesthetic containing a vasoconstrictor. Phentolamine mesylate is a nonselective alpha-adrenergic-blocking agent which is used for the reversal of this soft-tissue local anesthesia. This drug adds a new dimension to the pain management armamentarium of dentists.

 

Keywords: Antidote, local anesthesia, dentistry

Downloads

Published

2019-03-28

Issue

Vol. 5 No. 1 (2014)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.